Johnson & Johnson unit Janssen Pharmaceutical Companies is set to start a Phase Ib/II clinical trial to evaluate the safety and efficacy of JNJ-68284528 in patients with relapsed or refractory multiple myeloma.

The open-label, multicentre trial comes after FDA approved the company’s investigational new drug (IND) application.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Janssen expects to begin patient enrolment in the second half of this year.

The primary endpoint of the Phase Ib portion of the trial is to characterise the safety and establish the dose of JNJ-68284528.

The trial’s Phase II primary objective is to evaluate the efficacy of JNJ-68284528.

Other primary endpoints of the trial include overall response rate as defined by the International Myeloma Working Group response criteria.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We are hopeful that this BCMA targeted CAR-T therapy will play an important role in the treatment of this disease.”

Janssen research and development oncology global therapeutic area head Peter Lebowitz said: “As we strive to eliminate multiple myeloma, we are hopeful that this BCMA targeted CAR-T therapy will play an important role in the treatment of this disease.”

Last December, Janssen signed a collaboration and licence agreement with Legend Biotech USA and Legend Biotech Ireland for the joint development and commercialisation of JNJ-68284528 in multiple myeloma.

JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B cell maturation antigen (BCMA), was developed on the basis of Legend’s LCAR-B38M CAR-T cells platform.

CAR-T cells are a new approach to eliminate cancer cells by harnessing the power of a patient’s own immune system, while BCMA is a protein that is highly expressed on myeloma cells.

By targeting BCMA through a CAR-T approach, therapies could redefine the treatment scenario for multiple myeloma and could advance the development of cures for patients.